



The Challenge and Excitement of Discovering New Medicines

Dr Menelas Pangalos PhD, FSOB, FMedSci

Executive Vice President, AstraZeneca

7.30pm, Monday 18th January, 2016 Wolfson Hall Lecture Theatre, Churchill College, Storey's Way, Cambridge

The Lecture:

Dr Menelas Pangalos writes:

At AstraZeneca, our purpose is to push the boundaries of science to deliver life-changing medicines. The future treatment for many of today's diseases lies in discovering new biology, and understanding and challenging scientific hypotheses, to develop novel therapies. The advent of the genomics revolution brings with it an expanding list of pathways and targets to pursue - and with it new drug discovery challenges. By combining new technologies with medical understanding, we are making progress in our ability to define and deliver novel treatments for a variety of complex diseases. We also recognise that to be successful we need to work in partnership. Our teams continue to find innovative ways of collaborating with the best academic and industrial partners.

About the Speaker:

Mene Pangalos, Ph.D. is Executive Vice President of AstraZeneca's Innovative Medicines and Early Development Biotech Unit. A member of the company's Senior Executive team, Mene has overall responsibility for the company's small molecule discovery research and early development activities.

As one of AstraZeneca's leading scientists Mene has published more than 140 peer-reviewed articles in scientific journals and has served as an editor of books and journals in neuroscience.

Mene completed his undergraduate degree in Biochemistry at Imperial College of Science and Technology and earned a PhD in Neurochemistry from the Institute of Neurology, both at the University of London. He is a Visiting Professor of Neuroscience at King's College London.




In the UK, Mene sits on the Medical Research Council (MRC), the council for the National Centre for Universities and Business, the Prime Minister's Research Champion Group for Dementia and is part of the Ministerial Industry Strategy Group. He is a Fellow of the Academy of Medical Sciences and the Society for Biology, an Associate of the Royal College of Science and holds memberships with the American Society of Neuroscience and the British Pharmacology Society.

Throughout his career Mene has been recognised for driving forward scientific innovation. At Wyeth his group was recognised by R&D Directions magazine as having the Best Central Nervous System Pipeline, while in 2008 Mene was awarded an Innovation in Industry award by the New York Academy of Sciences for his outstanding contribution to neuroscience research and drug discovery.

Since joining AstraZeneca in 2010, Mene has been instrumental in transforming the company's commitment to science. He has led the transformation of R&D productivity through the development and implementation of the "5R" framework (recently published in Nature Reviews Drug Discovery); driven greater collaboration with academic, NGO and peer organisations; pioneered programmes to promote more open innovation, and fostered a science driven culture that rewards truth-seeking behaviours.

Mene is also overseeing the creation of AstraZeneca's new £330 million research centre in Cambridge - a state of the art of facility designed to stimulate collaborative scientific innovation and which will play an important role in the future success of the UK life science industry.

Practical Matters



Those attending the CSAR lecture may park in the Senior Car Park on Churchill Road, which is off Storey's Way. More parking is available further along Churchill Road, and in the Möller Centre at the far end.

CSAR lectures are open to all; CSAR members are admitted free. Pupils and students may register for free membership at the lecture reception desk.

Non-members are asked to make a nominal contribution of £3.00.

Coffee and biscuits are available in the Wolfson Foyer from around 7pm. For further directions, see: www.chu.cam.ac.uk/about/visitors/directions.php

Microsoft Research

CSAR is very grateful to Microsoft Research for sponsorship of CSAR lectures and student awards